Bank of America Lowers CVS Health (NYSE:CVS) Price Target to $95.00

CVS Health (NYSE:CVS) had its target price reduced by research analysts at Bank of America from $100.00 to $95.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the pharmacy operator’s stock. Bank of America‘s target price indicates a potential upside of 28.09% from the stock’s previous close.

Several other brokerages also recently weighed in on CVS. Raymond James Financial raised their price target on shares of CVS Health from $75.00 to $90.00 in a research report on Friday, October 31st. Robert W. Baird boosted their price target on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. TD Cowen increased their price objective on CVS Health from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Argus upped their target price on shares of CVS Health from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, The Goldman Sachs Group boosted their price objective on shares of CVS Health from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Twenty equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $94.86.

CVS Health Stock Down 11.6%

Shares of CVS Health stock traded down $9.70 during midday trading on Tuesday, hitting $74.17. The company had a trading volume of 9,860,419 shares, compared to its average volume of 7,858,034. The company has a 50 day moving average of $79.17 and a 200 day moving average of $74.97. The stock has a market capitalization of $94.15 billion, a P/E ratio of 196.58, a P/E/G ratio of 0.76 and a beta of 0.48. CVS Health has a 52-week low of $53.36 and a 52-week high of $85.15. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.63 and a current ratio of 0.83.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.24. The firm had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The company’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the company earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, equities analysts predict that CVS Health will post 5.89 earnings per share for the current fiscal year.

Institutional Trading of CVS Health

Hedge funds and other institutional investors have recently modified their holdings of the company. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares in the last quarter. Alteri Wealth LLC lifted its holdings in shares of CVS Health by 3.2% in the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after buying an additional 131 shares in the last quarter. TOWER TRUST & INVESTMENT Co grew its stake in CVS Health by 0.8% during the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after acquiring an additional 132 shares in the last quarter. Holistic Financial Partners increased its holdings in CVS Health by 4.1% in the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after acquiring an additional 133 shares during the last quarter. Finally, CYBER HORNET ETFs LLC lifted its stake in CVS Health by 4.1% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 134 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Neutral Sentiment: Analyst forecasts page shows updated price-targets and consensus projections that investors will watch for guidance changes after recent headlines. CVS Health Corporation (CVS) Stock Forecasts
• Neutral Sentiment: Zacks notes CVS is a trending ticker and flags fundamentals and recent attention — useful background but not new catalysts. CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Zacks Analyst Blog mention (broader market context); not a direct CVS catalyst but part of investor chatter. The Zacks Analyst Blog Microsoft, Anheuser-Busch CVS, and Stran & Co
• Negative Sentiment: Barron’s reports Humana, UnitedHealth and CVS shares plunged after the administration proposed keeping Medicare Advantage rates roughly flat, which trims revenue expectations for insurers and PBMs. Humana, UnitedHealth, and CVS Stocks Plunge After Medicare Rates Blow
• Negative Sentiment: CNBC: investors sold health insurers and related stocks in extended trading after the Trump administration proposed nearly flat Medicare Advantage rates, hitting CVS shares hard. Health insurers tumble after Trump administration proposes keeping Medicare Advantage rates flat next year
• Negative Sentiment: Reuters reports the administration’s draft would raise payments to insurers by roughly 0.09% on average — a near-flat change that lowers the revenue outlook for MA players and PBMs like CVS Caremark. Trump Administration proposes keeping steady Medicare rates paid to insurers, WSJ reports
• Negative Sentiment: Investing.com coverage highlights the market reaction: CVS and other health names tumbled on the lower Medicare rate proposal, signaling investor worry about near-term top-line pressure. CVS Health, UnitedHealth Group stocks tumble on lower Medicare rate proposal
• Negative Sentiment: HealthCareDive reports a House Judiciary investigation alleges CVS shut out rival pharmacy hubs — increasing regulatory and legal risk that could pressure margins and contracts. CVS accused of shutting out rival pharmacy hubs in House Judiciary investigation
• Negative Sentiment: FierceHealthcare summarizes a House report alleging CVS sought to stifle pharmacy-hub competition — a potential source of fines, contract limits, or remediation that investors will watch. House report alleges CVS aimed to stifle pharmacy hub competition
• Negative Sentiment: BizJournal profile notes CVS is simultaneously positioning as a healthcare partner while fighting Congress, the FTC and courts — reinforcing regulatory uncertainty for investors. Woonsocket-based CVS battles Congress, FTC and courts while positioning itself as healthcare reform partner

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.